Print Friendly, PDF & Email

NCT/Study#

NCT04919811 /

AB-106-G208

Taletrectinib In ROS1 Positive Lung Cancer Phase 2 Global Study

DISEASE GROUP:
Lung Cancer Clinical Trials
current phase:
II
STUDY STATUS:
Active
Location:
For More information: